 |
|
|
|
|
Insulin Pathway: Tumor Necrosis Factor Receptor (TNFR)
 | | |  Antibodies |
|
|
|
|
|
| Anti-TNFR (Ab-1) Mouse mAb (16803.1) |
ELISA, IB, NT |
human |
GR28L |
| Anti-TNFR-1 (29-44) Rabbit pAb |
IB, IH, IP |
bovine, canine, Drosophila, hamster, human, monkey, mouse, porcine, rabbit, rat, Xenopus, yeast |
654216 |
|
| | | | Proteins/Enzymes |
|
|
|
| Tumor Necrosis Factor Receptor I, Soluble, Human, Recombinant, E. coli |
PF055 |
|
| | | | Additional Information | | | | | | | | |
| Protein : TNFRSF6
| | |
|---|
| Name | TNFRSF6 |
|---|
| Description | tumor necrosis factor receptor superfamily, member 6 |
|---|
| Owner | Public |
|---|
| URN | urn:agi-llid:355 |
|---|
| Connectivity | 184 |
|---|
| Notes | The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor contains a death domain. It has been shown to play a central role in the physiological regulation of programmed cell death, and has been implicated in the pathogenesis of various malignancies and diseases of the immune system. The interaction of this receptor with its ligand allows the formation of a death-inducing signaling complex that includes Fas-associated death domain protein (FADD), caspase 8, and caspase 10. The autoproteolytic processing of the caspases in the complex triggers a downstream caspase cascade, and leads to apoptosis. This receptor has been also shown to activate NF-kappaB, MAPK3/ERK1, and MAPK8/JNK, and is found to be involved in transducing the proliferating signals in normal diploid fibroblast and T cells. At least eight alternatively spliced transcript variants encoding seven distinct isoforms have been described. The isoforms lacking the transmembrane domain may negatively regulate the apoptosis mediated by the full length isoform. |
|---|
| Hugo ID | 11920 |
|---|
| | |
|---|
| Microarray ID | D26112_s_at |
|---|
| | 102921_s_at |
|---|
| | 1460251_at |
|---|
| | affx-murfas_at |
|---|
| | m83649_s_at |
|---|
| | A_65_P14240 |
|---|
| | A_51_P345393 |
|---|
| | M67454 |
|---|
| | 204780_s_at |
|---|
| | 215719_x_at |
|---|
| | 216252_x_at |
|---|
| | 237522_at |
|---|
| | 37644_s_at |
|---|
| | 37643_at |
|---|
| | 44618_at |
|---|
| | 204781_s_at |
|---|
| | 1440_s_at |
|---|
| | 1441_s_at |
|---|
| | 1808_s_at |
|---|
| | 389_s_at |
|---|
| | x63717_at |
|---|
| | x82279_s_at |
|---|
| | x83490_s_at |
|---|
| | x83492_s_at |
|---|
| | x89101_s_at |
|---|
| | x83492_at |
|---|
| | A_23_P63896 |
|---|
| | A_14_P133882 |
|---|
| | A_14_P115129 |
|---|
| | A_14_P120036 |
|---|
| | M20 |
|---|
| | R072 |
|---|
| | OR0238 |
|---|
| | 239 |
|---|
| | 300 |
|---|
| | OH7658 |
|---|
| | OH7693 |
|---|
| | MB615 |
|---|
| | 1369900_at |
|---|
| | Msa.635.0_at |
|---|
| | M83649.1 |
|---|
| | NM_007987 |
|---|
| | 233820_at |
|---|
| | RC_AA018441_at |
|---|
| | 40153_AT |
|---|
| | 41184_S_AT |
|---|
| | I_931575 |
|---|
| | |
|---|
| Chromosome position | 19 23.0 cM |
|---|
| | 10q24.1 |
|---|
| | 1q52 |
|---|
| | |
|---|
| GO ID | GO:0004872 |
|---|
| | GO:0004888 |
|---|
| | GO:0006915 |
|---|
| | GO:0006955 |
|---|
| | GO:0007165 |
|---|
| | GO:0016020 |
|---|
| | GO:0016021 |
|---|
| | GO:0006924 |
|---|
| | GO:0005615 |
|---|
| | GO:0016329 |
|---|
| | GO:0006916 |
|---|
| | GO:0006917 |
|---|
| | GO:0006461 |
|---|
| | GO:0005829 |
|---|
| | GO:0005625 |
|---|
| | GO:0005887 |
|---|
| | GO:0008372 |
|---|
| | GO:0005888 |
|---|
| | 0004872 |
|---|
| | 0006915 |
|---|
| | 0006924 |
|---|
| | 0006925 |
|---|
| | 0006927 |
|---|
| | 0008625 |
|---|
| | 0009897 |
|---|
| | 0045060 |
|---|
| | 0005031 |
|---|
| | 0005901 |
|---|
| | 0004888 |
|---|
| | 0005515 |
|---|
| | 0005625 |
|---|
| | 0005829 |
|---|
| | 0006461 |
|---|
| | 0006916 |
|---|
| | 0006917 |
|---|
| | 0006955 |
|---|
| | 0007165 |
|---|
| | 0016020 |
|---|
| | 0016021 |
|---|
| | 0042981 |
|---|
| | |
|---|
| Alias | Fas |
|---|
| | APO-1 |
|---|
| | lpr |
|---|
| | E230016K23Rik |
|---|
| | RIKEN cDNA E230016K23 gene |
|---|
| | Tumor necrosis factor receptor superfamily, member 6 |
|---|
| | lymphoproliferation |
|---|
| | apoptosis-mediating surface antigen Fas precursor |
|---|
| | (FAS) |
|---|
| | lymphoproliferation protein |
|---|
| | atp1 |
|---|
| | Apo-1 antigen |
|---|
| | APO-1 cell surface antigen |
|---|
| | apoptosis (APO-1) antigen 1 |
|---|
| | Apoptosis-mediating surface antigen FAS |
|---|
| | APT1 |
|---|
| | CD95 |
|---|
| | Fas antigen |
|---|
| | FAS1 |
|---|
| | FASTM |
|---|
| | TNFR6 |
|---|
| | Tnfrsf6 |
|---|
| | TNR6 |
|---|
| | TNR6_HUMAN |
|---|
| | Fas antigen (ATP1) |
|---|
| | apoptosis (APO-1) antigen I |
|---|
| | apoptosis antigen I |
|---|
| | apoptosis antigen 1 |
|---|
| | FASL receptor |
|---|
| | Tumor necrosis factor receptor superfamily member 6 precursor |
|---|
| | otthump00000059646 |
|---|
| | alps1a |
|---|
| | cd95 antigen |
|---|
| | APT I |
|---|
| | APO I |
|---|
| | APO-1/FAS |
|---|
| | Fas receptors |
|---|
| | sFas |
|---|
| | FasR |
|---|
| | Fas receptor |
|---|
| | LOC365454 |
|---|
| | FASL receptors |
|---|
| | FAS I |
|---|
| | |
|---|
| Organism | Mus musculus |
|---|
| | Rattus norvegicus |
|---|
| | Homo sapiens |
|---|
| | Human |
|---|
| | |
|---|
| FunctionalClass | tumor necrosis factor receptor |
|---|
| | protein binding |
|---|
| | transmembrane receptor |
|---|
| | receptor |
|---|
| | |
|---|
| KEGG pathway | Apoptosis |
|---|
| | Cytokine-cytokine receptor interaction |
|---|
| | MAPK signaling pathway |
|---|
| | |
|---|
| Keyword | death receptor |
|---|
| | death domain |
|---|
| | receptor binding activity |
|---|
| | synthetase |
|---|
| | transmembrane receptor |
|---|
| | desmoplakin |
|---|
| | protein)synthetase |
|---|
| | desmoplakins |
|---|
| | tumor necrosis factor |
|---|
| | microsome |
|---|
| | |
|---|
| GO Cellular Component | external side of plasma membrane |
|---|
| | caveola |
|---|
| | cytosol |
|---|
| | integral to membrane |
|---|
| | membrane |
|---|
| | soluble fraction |
|---|
| | extracellular space |
|---|
| | integral to plasma membrane |
|---|
| | cellular_component unknown |
|---|
| | proteoglycan integral to plasma membrane |
|---|
| | |
|---|
| GO Molecular Function | receptor activity |
|---|
| | transmembrane receptor activity |
|---|
| | apoptosis regulator activity |
|---|
| | |
|---|
| Cell Localization | Plasma membrane |
|---|
| | |
|---|
| Pathway | FAS signaling |
|---|
| | Death receptor signaling |
|---|
| | Apoptosis |
|---|
| | Mitochondrial control of Apoptosis |
|---|
| | p38 Signaling |
|---|
| | FasL |
|---|
| | TNFRSF6 -> MYC signalling pathway |
|---|
| | TNFRSF6 -> HIF1A signalling pathway |
|---|
| | TNFRSF6 -> TP53 signalling pathway |
|---|
| | TNFRSF6 -> HSF1 signalling pathway |
|---|
| | TNFRSF6 -> HSPCA signalling pathway |
|---|
| | TNFRSF6 -> BCL6 signalling pathway |
|---|
| | TNFRSF6 -> BRCA1 signalling pathway |
|---|
| | TNFRSF6 -> JUN signalling pathway |
|---|
| | TNFRSF6 -> FOXO3A signalling pathway |
|---|
| | TNFRSF6 -> FOS signalling pathway |
|---|
| | TNFRSF6 -> SP1 signalling pathway |
|---|
| | TNFRSF6 -> SREBF1 signalling pathway |
|---|
| | TNFRSF6 -> SRF signalling pathway |
|---|
| | TNFRSF6 -> CDX2 signalling pathway |
|---|
| | TNFRSF6 -> PML signalling pathway |
|---|
| | TNFRSF6 -> CREB1 signalling pathway |
|---|
| | TNFRSF6 -> ATF2 signalling pathway |
|---|
| | TNFRSF6 -> DDIT3 signalling pathway |
|---|
| | TNFRSF6 -> E2F1 signalling pathway |
|---|
| | TNFRSF6 -> RELA signalling pathway |
|---|
| | TNF-TNFRSF6 |
|---|
| | TNFSF10-TNFRSF6 |
|---|
| | TNFSF4-TNFRSF6 |
|---|
| | TNFSF5-TNFRSF6 |
|---|
| | TNFSF6-TNFRSF6 |
|---|
| | TNFSF7-TNFRSF6 |
|---|
| | TNFSF8-TNFRSF6 |
|---|
| | TNFSF9-TNFRSF6 |
|---|
| | CB0480 Insulin |
|---|
| | |
|---|
| GO Biological Process | apoptosis |
|---|
| | induction of apoptosis via death domain receptors |
|---|
| | negative thymic T cell selection |
|---|
| | programmed cell death, activated T cells |
|---|
| | programmed cell death, inflammatory cells |
|---|
| | programmed cell death, transformed cells |
|---|
| | anti-apoptosis |
|---|
| | immune response |
|---|
| | induction of apoptosis |
|---|
| | protein complex assembly |
|---|
| | regulation of apoptosis |
|---|
| | signal transduction |
|---|
| | negative thymic T-cell selection |
|---|
| | programmed cell death, activated T-cells |
|---|
| | |
|---|
| State | tumor necrosis factor receptor superfamily, member 6 isoform 1 precursor |
|---|
| | tumor necrosis factor receptor superfamily, member 6 isoform 2 precursor |
|---|
| | tumor necrosis factor receptor superfamily, member 6 isoform 3 precursor |
|---|
| | tumor necrosis factor receptor superfamily, member 6 isoform 4 precursor |
|---|
| | tumor necrosis factor receptor superfamily, member 6 isoform 5 precursor |
|---|
| | tumor necrosis factor receptor superfamily, member 6 isoform 6 precursor |
|---|
| | tumor necrosis factor receptor superfamily, member 6 isoform 7 precursor |
|---|
| | isoform 1 precursor |
|---|
| | isoform 2 precursor |
|---|
| | isoform 3 precursor |
|---|
| | isoform 4 precursor |
|---|
| | isoform 5 precursor |
|---|
| | isoform 6 precursor |
|---|
| | isoform 7 precursor |
|---|
| | |
|---|
| State Description | Transcript Variant: This variant (1) encodes the longest isoform (1). |
|---|
| | Transcript Variant: This variant (2) lacks an in-frame coding segment compared to variant 1, resulting an isoform (2) that lacks an internal region, as compared to isoform 1. |
|---|
| | Transcript Variant: This variant (5) lacks two coding segments, which leads to a translation frameshift, compared to variant 1. The resulting isoform (5) contains a distinct and shorter C-terminus, as compared to isoform 1. |
|---|
| | Transcript Variant: This variant (6) lacks two coding segments, which leads to a translation frameshift, compared to variant 1. The resulting isoform (6) contains a distinct and shorter C-terminus, as compared to isoform 1. |
|---|
| | Transcript Variant: This variant (7) lacks a coding segment, which leads to a translation frameshift, compared to variant 1. The resulting isoform (7) contains a distinct and shorter C-terminus, as compared to isoform 1. |
|---|
| | Transcript Variant: This variant (3) lacks a coding segment, which leads to a translation frameshift, compared to variant 1. The resulting isoform (3) contains a distinct and shorter C-terminus, as compared to isoform 1. |
|---|
| | Transcript Variant: This variant (4) lacks a coding segment, which leads to a translation frameshift, compared to variant 1. The resulting isoform (4) contains a distinct and shorter C-terminus, as compared to isoform 1. |
|---|
| | Transcript Variant: This variant (8) lacks two coding segments, which leads to a translation frameshift, compared to variant 1. The resulting isoform (4) contains a distinct and shorter C-terminus, as compared to isoform 1. |
|---|
|
|
 |
|
|
